MannKind Corp. Stock
Price
Target price
€4.68
€4.68
-3.450%
-0.168
-3.450%
€8.62
10.11.25 / Tradegate
WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
MannKind Corp. Stock
MannKind Corp. took a tumble today and lost -€0.168 (-3.450%).
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
As a result the target price of 8 € shows a very positive potential of 70.83% compared to the current price of 4.68 € for MannKind Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for MannKind Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of MannKind Corp. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -3.450% | -1.988% | 11.314% | -30.848% | -28.175% | 11.116% | 97.345% |
| Ardelyx Inc. | -1.130% | 8.658% | 24.612% | 15.055% | 6.667% | 333.672% | 8.214% |
| Krystal Biotech | 1.330% | -0.933% | 11.981% | -4.704% | 15.145% | 130.592% | - |
| Evolus Inc | -3.330% | 6.306% | 14.563% | -51.240% | -43.810% | -16.901% | 115.959% |
Comments
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Wells Fargo & Company from $10.00 to $8.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind (MNKD) Q2 Revenue Rises 6%
MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from
